Edwards Lifesciences Corporation (NYSE:EW)‘s stock had its “buy” rating reaffirmed by research analysts at Royal Bank Of Canada in a research note issued on Friday. They presently have a $130.00 price target on the medical research company’s stock. Royal Bank Of Canada’s target price points to a potential upside of 14.73% from the stock’s previous close.

EW has been the subject of a number of other research reports. BidaskClub lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Canaccord Genuity reiterated a “buy” rating and set a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $129.00 price objective for the company in a research note on Thursday, June 1st. Goldman Sachs Group, Inc. (The) assumed coverage on Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They set a “conviction-buy” rating and a $138.00 price objective for the company. Finally, Cowen and Company reiterated an “outperform” rating and set a $135.00 price objective (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Edwards Lifesciences Corporation has an average rating of “Buy” and a consensus target price of $120.75.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 113.31 on Friday. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75. The company has a 50 day moving average price of $115.12 and a 200 day moving average price of $107.54. The company has a market cap of $23.93 billion, a price-to-earnings ratio of 34.37 and a beta of 0.64.

Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. The company had revenue of $842 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted $0.76 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Edwards Lifesciences Corporation (EW) Given “Buy” Rating at Royal Bank Of Canada” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/02/edwards-lifesciences-corporation-ew-given-buy-rating-at-royal-bank-of-canada.html.

In related news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $118.05, for a total value of $3,883,845.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $117.15, for a total value of $656,040.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 163,541 shares of company stock worth $18,896,959. 2.13% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Korea Investment CORP boosted its position in shares of Edwards Lifesciences Corporation by 24.1% in the first quarter. Korea Investment CORP now owns 43,016 shares of the medical research company’s stock valued at $4,047,000 after buying an additional 8,365 shares in the last quarter. Profund Advisors LLC boosted its position in shares of Edwards Lifesciences Corporation by 14.2% in the first quarter. Profund Advisors LLC now owns 8,703 shares of the medical research company’s stock valued at $819,000 after buying an additional 1,083 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of Edwards Lifesciences Corporation by 29.7% in the first quarter. ProShare Advisors LLC now owns 33,226 shares of the medical research company’s stock valued at $3,126,000 after buying an additional 7,615 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD boosted its position in shares of Edwards Lifesciences Corporation by 7.3% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 17,403 shares of the medical research company’s stock valued at $1,637,000 after buying an additional 1,191 shares in the last quarter. Finally, BB&T Corp boosted its position in shares of Edwards Lifesciences Corporation by 6.3% in the first quarter. BB&T Corp now owns 6,836 shares of the medical research company’s stock valued at $643,000 after buying an additional 403 shares in the last quarter. Institutional investors and hedge funds own 82.36% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.